In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Atrial fibrillation ablation European survey: short-term results.

Atrial Fibrillation

Josep Brugada Terradellas, FESC Josep Brugada Terradellas (Spain)

Presentation webcast

Presentation slides

List of Authors:
Elena Arbelo, Gerhard Hindriks, Aldo Maggioni, John Morgan, Luigi Tavazzi, Panos Vardas, Josep Brugada


Aims: The Atrial Fibrillation Ablation Pilot Study is a prospective, multicentre, sentinel registry that has been designed to describe the clinical epidemiology of patients undergoing an atrial fibrillation (AFib) ablation procedure, and the diagnostic/therapeutic processes applied in these patients across Europe.

Methods and results: A total of 74 Centres in 10 European countries were asked to enrol 20 consecutive patients undergoing a first AFib ablation procedure. Between October 2010 and May 2011, 1410 patients were included, of which 1391 underwent an AFib ablation (98.7%). The median age was 60 years (IQR 52–66), and 28% females. History of stroke was seen in 7% of patients. Two thirds presented paroxysmal AFib and 38% were diagnosed of lone AFib. Symptoms were present in 86% of cases. The indications for ablation were mostly symptomatic AFib, but in over a third of patients, there was also a desire for a drug-free lifestyle and the maintenance of sinus rhythm. The ablation was performed with an open irrigation in 78%.
Complications occurred in 7.7%. Cardiac perforation was reported in 0.8% of patients and a cardioembolic event in 0.6%. The median duration of hospitalization was 3 days (IQR 2–4). At discharge, 91.4% of patients were in sinus rhythm, 87.4% of patients were given vitamin K antagonists and 67% antiarrhythmic medication. There was one cardiovascular death non-related to the ablation procedure.

Conclusion: The Atrial Fibrillation Ablation Pilot Study provides relevant information with regards to the current clinical practice across Europe. These data may prove useful when designing management strategies of patients suffering from AFib.




Clinical Registry Highlight I - Risk and treatment reality

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.